{
    "title": "Cobalt Hexammine vs Ebola",
    "inventor_name": "Eddie Chang",
    "publication_year": 2011,
    "device_name": "Cobalt Hexammine (CoHex)",
    "goal": "Provide a broad-spectrum antiviral therapeutic for viruses such as Ebola, HIV, and others.",
    "problem_addressed": "Lack of effective drugs for emerging viral infections (Ebola, HIV, H1N1) and drug-resistant strains.",
    "concept_summary": "Hexamminecobalt(III) chloride (CoHex) is a kinetically inert, water-soluble cobalt(III) complex that interacts with biological systems primarily through outer-sphere coordination and electrostatic forces. Laboratory studies report inhibition of protein synthesis, dose-dependent antiviral activity against a wide range of viruses (ssRNA, dsRNA, dsDNA, enveloped and non-enveloped), and lower cytotoxicity than approved drugs such as cis-platin.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "outer-sphere coordination",
        "electrostatic interaction",
        "kinetic inertness of Co(III) complex",
        "protein synthesis inhibition"
    ],
    "scientific_domains": [
        "Chemistry",
        "Virology",
        "Pharmacology"
    ],
    "mechanisms_of_action": [
        "outer-sphere coordination with viral components",
        "electrostatic interaction disrupting viral replication",
        "steric blockade of protein synthesis",
        "inhibition of viral protein synthesis"
    ],
    "materials": [
        "hexamminecobalt(III) chloride",
        "cobalt(III) complex",
        "ammonia ligands",
        "chloride ions"
    ],
    "energy_sources": [],
    "inputs": [
        "viral infection (cell culture or animal model)",
        "administration of CoHex compound"
    ],
    "outputs": [
        "reduction of viral replication",
        "lower cytotoxicity compared to cis-platin",
        "potential additive effect with existing antivirals"
    ],
    "claimed_performance": "Broad-spectrum antiviral activity against Sindbis, HIV-1, Zaire Ebola virus, and many other ssRNA, dsRNA, dsDNA viruses; lower cytotoxicity than FDA-approved cis-platin; additive effect with existing antiviral drugs.",
    "experimental_evidence": "Initial in-vitro studies show inhibition of Sindbis, HIV-1 and Ebola viruses; small-animal testing indicates much lower cytotoxicity than cis-platin; reported by Naval Research Laboratory and US Navy.",
    "replication_status": "Reported by Naval Research Laboratory and patents; no independent replication documented in the article.",
    "keywords": [
        "cobalt hexammine",
        "CoHex",
        "antiviral",
        "broad-spectrum",
        "Ebola",
        "HIV",
        "protein synthesis inhibition",
        "kinetic inertness"
    ],
    "related_technologies": [
        "broad-spectrum antiviral drugs",
        "metal-complex therapeutics",
        "adjunct antiviral therapy"
    ],
    "controversy_level": "low",
    "confidence_score": 0.85,
    "practicability_score": 0.7,
    "fringe_score": 0.2,
    "evidence_strength": 0.6,
    "risk_score": 0.3,
    "trl_estimate": 5,
    "source_urls": [
        "http://www.soflacs.org/semknightmar15.pdf",
        "http://chemistry.fiu.edu/seminars/2011/seminar-on-wednesday-april-6th-at-11am/abstract.pdf",
        "http://www.nrl.navy.mil/techtransfer/available-technologies/biomolecular-engineering/CoHex",
        "http://www.nrl.navy.mil/techtransfer/sites/www.nrl.navy.mil.techtransfer/files/files/cohex.pdf",
        "http://en.wikipedia.org/wiki/Hexamminecobalt%28III%29_chloride",
        "http://ed.augie.edu/~awaspaas/inorg/hexaammine.pdf",
        "http://genchem.rutgers.edu/Coam.html",
        "http://www.sigmaaldrich.com/catalog/product/sigma/h7891?lang=en&region=US"
    ],
    "organizations": [
        "Naval Research Laboratory",
        "US Navy",
        "Florida Institute of Technology"
    ],
    "applications": [
        "Therapeutic treatment of viral infections (Ebola, HIV, influenza)",
        "First-responder stockpiles for outbreak response",
        "Adjunct therapy to reduce dosage of existing antivirals"
    ],
    "limitations": [
        "Limited pre-clinical data; no human clinical trials reported",
        "Regulatory approval pathway not addressed",
        "Scale-up and manufacturing costs not discussed"
    ],
    "open_questions": [
        "Exact molecular mechanism of antiviral activity",
        "Efficacy and safety in humans",
        "Potential for resistance development"
    ],
    "red_flags": [
        "Claims are based on early-stage pre-clinical data only"
    ],
    "evidence_quotes": [
        "Cohex is a small, stable, water-soluble, and inexpensive compound that can potentially be used as a therapeutic when there is no known drug therapy available, such as the case with H1N1 or an Ebola outbreak.",
        "Initial small animal testing also shows that CoHex has a much lower cytotoxicity than FDA approved cis-Platin making it a good source as a therapeutic agent.",
        "Cohex shows broad spectrum anti-viral activity against Sindbis, HIV-1 and Zaire Ebola virus.",
        "Due to its kinetic inertness, Cohex interacts principally with its environment via outer-sphere coordination and through simple electrostatic interaction.",
        "The compound is air and water stable and has low toxicity."
    ]
}